PACE 319 . RCVD AT 1128/2004 9:49:53 AM [Eastern Standard Time] " SVR:USPTO-EFXRF-117" DNGS-8729306 " CSID:977 781 8064" DURATION (mm-55):02-64

CASE 4-33182A

CERTIFICATE OF FACSIMILE TRANSMISSION

hereby certify that this paper (along with any paper referg attached or enclosed) is being facelmile transmitted to the Patent and Trademark Office on the date shown below.

David E Wildman

Type or print name

ary 28, 2004

Dala

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1614

MICHAEL WYLLIE

Examiner: Jones, Dwayne C.

APPLICATION NO: 09/778,290

FILED: FEBRUARY 7, 2001

FOR: PHARMACEUTICAL COMBINATIONS

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

PETITION FOR EXTENSION OF TIME

Sir.

The Office Action of July 28, 2003 has a shortened statutory time set to expire on October 28, 2003. A three-month extension is hereby requested pursuant to 37 CFR §1.136(a).

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$950 for payment of the extension fee. An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees under 37 CFR §1.17 which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Respectfully submitted.

Novartis Corporate Intellectual Property One Health Plaza, Building 430 East Hanover, NJ 07938-1080

02/11/2004 GDUCKETT 00000007 190134 Date: January 28,

01 FC:1253

950.00 DA

David E. Wildman Attorney for Applicant Reg. No. 40,226

Phone No. (862) 778-7954